Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Fast Track + PR (CR) = Accelerated Approval

<< Previous

Bullboard Posts

Next >>

Post by SundayMovieson Dec 04, 2022 1:27pm

368 Views

Post# 35149593

Fast Track + PR (CR) = Accelerated Approval

Things have dramatically changed and the market is behind the curve.
Fast Track by FDA opens the door for an Accelerated Approval.
Partial Responses and 1 complete responses will be enought for a licensing deal for a an Accelrated Approval.

We move much much higher.

I added more and will wait for the market to follow.

<< Previous

Bullboard Posts

Next >>

Rick Rule’s election insights: Gold, USD, and Canadian gas